||Recombinant Human SUMO1 (Accession # NM_003352) , fused with a C-terminal Aminoluciferin (AML), was produced in E. coli-derived.
||X mg/ml (X µM) in 50 mM HEPES pH 7.5, 100 mM NaCl
||Recombinant Human SUMO1-Aminoluciferin (AML) is ideal for use as a SUMO-specific isopeptidase enzyme substrate. Isopeptidase activity liberates luciferin from Recombinant Human SUMO1-Aminoluciferin (AML). ATP and luciferase are then added to produce a luminescent signal proportional to SUMO-specific isopeptidase activity. Optimal luminescence at pH 7.5 can be monitored using all wavelengths with a 500 ms integration time. Reaction conditions will need to be optimized for each specific application. We recommend an initial Recombinant Human SUMO1-Aminoluciferin (AML) concentration of 0.1-1 µM.
||Recombinant Human SUMO1 has a calculated MW of 11 kDa.
||>95%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).